Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
16 evidence topics · 8 sources
Absorption and time to peak concentration
Accumulation, peak-to-trough fluctuation, and effective half-life
“Steady-state PK profiles showed limited peak-to-trough fluctuation (range, 1.89–2.51), with an accumulation ratio of approximately 3 for Cmax (range, 1.96–3.55) and of approximately 4 for AUC0–24 (range, 3.63–5.20), and an effective half-life of approximately 70 h (range, 50.5 h to 77.2 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Terminal half-life
“Overall, palazestrant showed biphasic elimination in the distribution phase, which was similar to that observed with 120 mg palazestrant in healthy volunteers (data on file), confirming the 8-day terminal half-life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distribution and support for once-daily dosing
“PK analyses showed that palazestrant was readily bioavailable and rapidly absorbed (reaching peak concentration after 4 h), with extensive tissue distribution, dose-proportional exposure, and a long half-life of approximately 8 days. These PK characteristics support once-daily dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Steady-state exposure at the recommended phase 2 dose
“The steady-state geometric mean AUC0–24 was 4030 and 9210 h*ng/mL for 60 and 120 mg dose cohorts, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the RP2D of 120 mg (n = 73), the geometric mean Cmax at steady state was 541 ng/mL, and the geometric mean Cavg was 384 ng/mL, showing sustained concentrations above the predicted efficacy threshold” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Steady-state pharmacokinetic parameters at 60, 90, and 120 mg
Posted steady-state AUC by dose in the registry results
Time to peak concentration during dose escalation
Terminal half-life and peak-to-trough variability at the dose selection analysis
Exposure at 90 mg and 120 mg in combination with ribociclib
Plasma protein binding across species
Nonclinical oral half-life
“Compound 21 is orally bioavailable and has low clearance and a long half-life in the mouse, rat, dog, and monkey” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The half-lives after a single oral dose in the mouse, rat, dog, and monkey were 10, 16, 106, and 34 h, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote